Intelliseq
Slawomir Golda has a diverse work experience in the fields of genome informatics, molecular biology, and bioinformatics. Slawomir co-founded and served as the Chief Operations Officer at intelliseq, a genome informatics company, from 2013 to the present. In 2017, they became the Chief Financial Officer at Intelliseq Corp. Prior to that, from 2009 to 2017, Golda worked as a postdoc NGS specialist and molecular biologist at the Institute of Pharmacology, Polish Academy of Sciences. During their time there, they focused on identifying differences between neurons and glial cells in transcriptional sensitivity to glucocorticoids. Before that, they had an internship as a Clinical Research Associate at MDS Pharma Services in 2009 and worked as a Research Assistant at INSERM from 2005 to 2006.
Slawomir Golda has a strong education background in the field of biotechnology and oncology. Slawomir first pursued their Bachelor's degree in Biotechnology/Biophysics at Jagiellonian University from 1998 to 2003. Building upon this foundation, they then went on to complete their Doctor of Philosophy (Ph.D.) in Oncology and Cancer Biology at the same university from 2003 to 2008. Recently, in 2017 to 2018, they furthered their knowledge by undertaking postgraduate study in Clinical Trials - methodology, organization, and management, again at Jagiellonian University. Through these educational experiences, Slawomir Golda has developed a well-rounded understanding of various aspects of the biotechnology, oncology, and clinical trials fields.
This person is not in any teams
This person is not in any offices
Intelliseq
Intelliseq is a genome informatics company developing bioinformatics tools for diagnostics, therapy, and prevention based on genetic data. Currently bioinformatics systems in laboratories are not ready for genomics at scale. The analysis process of already sequenced genomes is now mostly expensive and labor-intensive. In response to this problemthe company created a cloud-based platform called IntelliseqFlow that allows for automated bioinformaticianless generation of result reports that accelerates the entire diagnostic process and reduces the costs that the laboratory had to deal with so far. IntelliseqFlow translates raw DNA data into final reports automatically, making the analysis step fast, simple, cost-effective and user-friendly. Allows users to choose ready-to-use workflows for PGx, Germline Disorders, Somatic Cancer, and Polygenic Risk Scoring all wrapped-up in one user-friendly platform. It comprises AI-based algorithms, easy to operate pipelines, customized workflows, and APIs that make it simple to integrate our engine with laboratory information systems.The company was established in 2014 by a group of scientists fascinated with pharmacogenomics and transcriptomics. Intelliseq’s products are currently being used by laboratories in Asia, Europe, and the US.